ASP Isotopes Inc. is a development-stage advanced materials company focused on the production, distribution, and sale of high-value isotopes. Based in Dallas, Texas, the company uses its proprietary Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE) technologies to separate isotopes for specialized end markets.
The business operates across two core segments. Its Nuclear Fuels segment advances technologies used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels market. Its Specialist Isotopes and Related Services segment develops methods to separate high-value, low-volume isotopes such as Carbon-14, Molybdenum-100, Silicon-28, and Ytterbium-176 for applications spanning nuclear medical imaging, pharmaceuticals and agrochemicals, and semiconductors. The company has also expanded into helium and LNG through its acquisition of Renergen.
Investors follow ASPI for its exposure to several long-duration secular themes, including the next generation of nuclear fuel, isotope supply for medical imaging, and semiconductor-grade materials. As a pre-profitability company funding a capital-intensive buildout, however, the stock carries meaningful execution and financing risk. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, ASPI has declined approximately 51%. The stock closed at $2.17 on October 21, 2026, and traded near $1.06 in recent sessions, a loss of more than half its value in a single month. The selling was broad-based and persistent, with the shares losing ground in most sessions through mid-November.
The quarterly picture is even more pronounced. About three months ago, in late August 2026, ASPI traded around $3.95. From that level, the stock has fallen roughly 73%, indicating that the recent 30-day move is part of a sustained multi-month downtrend rather than an isolated correction.
The consistent downward trajectory across both timeframes points to structural concerns, including balance-sheet pressure and execution risk, outweighing the company's top-line growth story.
Several factors combined to drive the sharp decline in ASPI shares over the last month. The most immediate catalyst was third-quarter earnings. Results reported in mid-November showed a net loss of roughly $30.4 million, or $0.21 per share, a meaningful widening from a loss of about $12.6 million, or $0.14 per share, in the prior-year period. Although revenue climbed roughly 303% to about $5.1 million, the larger loss underscored the rising cost of the company's development and expansion efforts and reinforced concerns about the pace of cash consumption.
Dilution has remained a persistent theme. The company's share count has grown substantially over the past year, driven in part by a convertible-note exchange that converted debt into newly issued common stock. Additional financing channels, including an at-the-market program and equity-linked arrangements, have kept supply-side pressure on the shares and weighed on investor confidence. From what I see, this supply pressure has been a key factor in the repricing.
Market commentary also turned cautious. Independent research questioned the company's track record of delivering commercial milestones, and at least one analyst downgraded the stock during the month. Combined with elevated short interest and a broader rotation away from speculative, pre-revenue nuclear and advanced-materials names, the result was a sustained repricing lower.
The quarterly decline reflects a larger narrative of a capital-intensive growth story meeting persistent financing realities. Throughout the quarter, investors weighed the company's ambitious expansion across nuclear fuels, isotope enrichment, and helium and LNG against a rising share count and widening losses.
Strategic developments provided some operational credibility, including a joint-venture framework for a HALEU production facility in South Africa and progress on helium production. However, these longer-dated initiatives did not offset near-term concerns about milestone timing and funding requirements. The company has repeatedly signaled that it will need to raise substantial additional capital, and the market has increasingly focused on the dilution and execution risk embedded in that outlook.
The result has been a steady erosion in the stock's valuation premium as investors reassessed the timeline to commercial scale and sustainable cash flow. I'm watching this closely as earnings updates come in.
Looking ahead, the key variables for ASPI are likely to be financial rather than purely operational. Investors will monitor the pace of cash burn, any new financing announcements, and changes to the share count, given the dilution that has already occurred.
Milestone delivery remains central. The company has outlined targets across its nuclear fuels, isotope enrichment, and helium and LNG segments, and the market is likely to reward tangible, on-time commercial progress while punishing further delays. Earnings and guidance updates will also be closely watched, particularly for evidence that revenue growth can narrow the gap with rising expenses.
Broader market conditions matter as well. Sentiment toward speculative, pre-profitability names in the nuclear and advanced-materials space can shift quickly, and ASPI's elevated volatility and notable short interest mean the stock can move sharply in either direction on news. Investors should weigh these risks carefully rather than treating any single data point as a definitive signal.
In my research process, I often review Tickeron’s Trending AI Robots to see which automated strategies are gaining traction on volatile names like this. The page highlights a curated selection of AI-driven trading bots from a platform that offers hundreds of automated strategies trading thousands of tickers. Only the top-performing and most relevant bots appear in this section, helping traders quickly identify active approaches rather than sorting through the full catalog. The bots vary widely in strategy, holding timeframe, and performance metrics, so no two are identical in how they approach the market. For investors following names such as ASPI, reviewing these automated strategies can provide an additional data-driven perspective on market behavior.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Aroon Indicator for ASPI entered a downward trend on November 20, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 190 similar instances where the Aroon Indicator formed such a pattern. In 169 of the 190 cases the stock moved lower. This puts the odds of a downward move at 89%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ASPI as a result. In 57 of 66 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for ASPI turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 31 similar instances when the indicator turned negative. In 25 of the 31 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASPI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +24.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASPI advanced for three days, in 198 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
ASPI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.202) is normal, around the industry mean (2.284). P/E Ratio (-1.634) is within average values for comparable stocks, (-17.137). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.548). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (11.062) is also within normal values, averaging (48.960).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. ASPI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASPI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ChemicalsSpecialty